How do ARDELYX, INC. and REGIS CORP compare by revenue?

ARDELYX, INC. reported revenue of $94.5M in Q1 FY2026, while REGIS CORP reported $57.1M in Q2 FY2026. ARDELYX, INC. is 1.7× larger by last-quarter revenue.

Which is growing revenue faster, ARDELYX, INC. or REGIS CORP?

ARDELYX, INC.'s latest revenue grew 27.5% year-over-year, versus 22.3% for REGIS CORP. ARDELYX, INC. is growing faster on a YoY basis.

Which has a higher net margin, ARDELYX, INC. or REGIS CORP?

ARDELYX, INC.'s net margin is -39.8% vs REGIS CORP's 0.8%. REGIS CORP has the higher bottom-line margin.

What is the 2-year revenue CAGR for ARDELYX, INC. vs REGIS CORP?

Over the trailing 8 quarters, ARDELYX, INC. compounded revenue at roughly 13.6% per year, versus 7.8% for REGIS CORP. ARDELYX, INC. has the faster medium-term growth trajectory.

Where does this ARDX vs RGS data come from?

All figures are parsed directly from SEC EDGAR 10-Q / 10-K / 20-F / 6-K filings (for US-listed issuers) or EDINET filings (for Japanese issuers), then normalised into a common schema. Numbers update automatically as new filings are released.

vs

Side-by-side financial comparison of ARDELYX, INC. (ARDX) and REGIS CORP (RGS). Click either name above to swap in a different company.

ARDELYX, INC. is the larger business by last-quarter revenue ($94.5M vs $57.1M, roughly 1.7× REGIS CORP). REGIS CORP runs the higher net margin — 0.8% vs -39.8%, a 40.6% gap on every dollar of revenue. On growth, ARDELYX, INC. posted the faster year-over-year revenue change (27.5% vs 22.3%). Over the past eight quarters, ARDELYX, INC.'s revenue compounded faster (13.6% CAGR vs 7.8%).

ARDELYX, INC.ARDXEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Ardelyx, Inc. is a commercial-stage biopharmaceutical firm developing and commercializing innovative therapies for gastrointestinal, cardiorenal and metabolic diseases with high unmet medical needs. Its lead product is approved in the US for irritable bowel syndrome with constipation, and it holds a robust pipeline of early and late-stage drug candidates.

REGIS CORPRGSEarnings & Financial Report

Nasdaq · Consumer Discretionary · Services-Personal Services

Regis Corporation is an American operator of hair salons. As of August 2021, it has 5,563 franchised and 276 company-owned salons. Its headquarters are in Minneapolis, Minnesota.

ARDX vs RGS — Head-to-Head

Bigger by revenue

ARDX

1.7× larger

$94.5M

$57.1M

Growing faster (revenue YoY)

ARDX

+5.2% gap

27.5%

22.3%

Higher net margin

RGS

40.6% more per $

0.8%

-39.8%

Faster 2-yr revenue CAGR

ARDX

Annualised

13.6%

7.8%

Income Statement — Q1 FY2026 vs Q2 FY2026

Metric	ARDX	RGS
Revenue	$94.5M	$57.1M
Net Profit	$-37.6M	$456.0K
Gross Margin	—	—
Operating Margin	—	10.8%
Net Margin	-39.8%	0.8%
Revenue YoY	27.5%	22.3%
Net Profit YoY	—	-94.0%
EPS (diluted)	$-0.15	$0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue

ARDX

RGS

Q1 26	$94.5M	—
Q4 25	$125.2M	$57.1M
Q3 25	$110.3M	$59.0M
Q2 25	$97.7M	$60.4M
Q1 25	$74.1M	$57.0M
Q4 24	$116.1M	$46.7M
Q3 24	$98.2M	$46.1M
Q2 24	$73.2M	$49.4M

Net Profit

ARDX

RGS

Q1 26	$-37.6M	—
Q4 25	$-407.0K	$456.0K
Q3 25	$-969.0K	$1.4M
Q2 25	$-19.1M	$116.5M
Q1 25	$-41.1M	$250.0K
Q4 24	$4.6M	$7.6M
Q3 24	$-809.0K	$-853.0K
Q2 24	$-16.5M	$91.2M

Gross Margin

ARDX

RGS

Q1 26	—	—
Q4 25	91.3%	—
Q3 25	96.4%	—
Q2 25	87.3%	—
Q1 25	83.4%	—
Q4 24	84.3%	—
Q3 24	84.0%	—
Q2 24	87.1%	—

Operating Margin

ARDX

RGS

Q1 26	—	—
Q4 25	4.1%	10.8%
Q3 25	4.2%	10.0%
Q2 25	-14.7%	12.1%
Q1 25	-49.0%	8.8%
Q4 24	7.0%	11.8%
Q3 24	2.3%	4.6%
Q2 24	-18.6%	—

Net Margin

ARDX

RGS

Q1 26	-39.8%	—
Q4 25	-0.3%	0.8%
Q3 25	-0.9%	2.3%
Q2 25	-19.5%	192.9%
Q1 25	-55.5%	0.4%
Q4 24	4.0%	16.4%
Q3 24	-0.8%	-1.9%
Q2 24	-22.5%	184.7%

EPS (diluted)

ARDX

RGS

Q1 26	$-0.15	—
Q4 25	$-0.01	$0.16
Q3 25	$0.00	$0.49
Q2 25	$-0.08	$43.67
Q1 25	$-0.17	$0.08
Q4 24	$0.01	$2.71
Q3 24	$0.00	$-0.36
Q2 24	$-0.07	$38.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric	ARDX	RGS
Cash + ST InvestmentsLiquidity on hand	$238.1M	$18.4M
Total DebtLower is stronger	$203.5M	$113.3M
Stockholders' EquityBook value	$148.6M	$188.7M
Total Assets	$504.5M	$588.3M
Debt / EquityLower = less leverage	1.37×	0.60×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments

ARDX

RGS

Q1 26	$238.1M	—
Q4 25	$68.0M	$18.4M
Q3 25	$42.7M	$16.6M
Q2 25	$90.0M	$17.0M
Q1 25	$30.8M	$13.3M
Q4 24	$64.9M	$10.2M
Q3 24	$47.4M	$6.3M
Q2 24	$41.9M	$10.1M

Total Debt

ARDX

RGS

Q1 26	$203.5M	—
Q4 25	$202.8M	$113.3M
Q3 25	$202.1M	$111.3M
Q2 25	$201.4M	$110.8M
Q1 25	$151.3M	$112.0M
Q4 24	$150.9M	$111.5M
Q3 24	$100.7M	$95.2M
Q2 24	$100.2M	$99.5M

Stockholders' Equity

ARDX

RGS

Q1 26	$148.6M	—
Q4 25	$166.9M	$188.7M
Q3 25	$154.3M	$187.6M
Q2 25	$139.5M	$185.6M
Q1 25	$145.7M	$68.6M
Q4 24	$173.3M	$66.7M
Q3 24	$158.3M	$56.4M
Q2 24	$147.0M	$56.8M

Total Assets

ARDX

RGS

Q1 26	$504.5M	—
Q4 25	$501.6M	$588.3M
Q3 25	$486.2M	$592.1M
Q2 25	$466.8M	$599.0M
Q1 25	$410.2M	$511.2M
Q4 24	$435.8M	$530.1M
Q3 24	$367.9M	$508.9M
Q2 24	$343.5M	$530.5M

Debt / Equity

ARDX

RGS

Q1 26	1.37×	—
Q4 25	1.21×	0.60×
Q3 25	1.31×	0.59×
Q2 25	1.44×	0.60×
Q1 25	1.04×	1.63×
Q4 24	0.87×	1.67×
Q3 24	0.64×	1.69×
Q2 24	0.68×	1.75×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric	ARDX	RGS
Operating Cash FlowLast quarter	—	$1.7M
Free Cash FlowOCF − Capex	—	$891.0K
FCF MarginFCF / Revenue	—	1.6%
Capex IntensityCapex / Revenue	—	1.4%
Cash ConversionOCF / Net Profit	—	3.65×
TTM Free Cash FlowTrailing 4 quarters	—	$14.9M